Efficacy of a real-time intelligent quality-control system for the detection of early upper gastrointestinal neoplasms: a multicentre, single-blinded, randomised controlled trial.

IF 9.6 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL
EClinicalMedicine Pub Date : 2024-08-30 eCollection Date: 2024-09-01 DOI:10.1016/j.eclinm.2024.102803
Ruchen Zhou, Jing Liu, Chenchen Zhang, Yusha Zhao, Jingran Su, Qiong Niu, Chengxia Liu, Zhuang Guo, Zhenqin Cui, Xiaoqin Zhong, Weidong Zhao, Jing Li, Xiaodong Zhang, Hongyan Wang, Shidong Sun, Ruiguang Ma, Xinyu Chen, Xinyan Xu, Yiqing Zhu, Zhen Li, Xiuli Zuo, Yanqing Li
{"title":"Efficacy of a real-time intelligent quality-control system for the detection of early upper gastrointestinal neoplasms: a multicentre, single-blinded, randomised controlled trial.","authors":"Ruchen Zhou, Jing Liu, Chenchen Zhang, Yusha Zhao, Jingran Su, Qiong Niu, Chengxia Liu, Zhuang Guo, Zhenqin Cui, Xiaoqin Zhong, Weidong Zhao, Jing Li, Xiaodong Zhang, Hongyan Wang, Shidong Sun, Ruiguang Ma, Xinyu Chen, Xinyan Xu, Yiqing Zhu, Zhen Li, Xiuli Zuo, Yanqing Li","doi":"10.1016/j.eclinm.2024.102803","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Oesophagogastroduodenoscopy (OGD) quality and identification of the early upper gastrointestinal (UGI) neoplasm play an important role in detecting the UGI neoplasm. However, the optimal method for quality control in daily OGD procedures is currently lacking. We aimed to evaluate the efficacy of a real-time intelligent quality-control system (IQCS), which combines OGD quality control with lesion detection of early UGI neoplasms.</p><p><strong>Methods: </strong>We performed a multicentre, single-blinded, randomised controlled trial at 6 hospitals in China. Patients aged 40-80 years old who underwent painless OGD were screened for enrolment in this study. Patients with a history of advanced UGI cancer, stenosis, or obstruction in UGI tract were excluded. Eligible subjects were randomly assigned (1:1) to either the routine or IQCS group to undergo standard OGD examination and OGD examination aided by IQCS, respectively. Patients were masked to the randomisation status. The primary outcome was the detection of early UGI neoplasms. All analyses were done on a per-protocol basis. This trial is registered with ClinicalTrials.gov, NCT04720924.</p><p><strong>Findings: </strong>Between January 16, 2021 and December 23, 2022, 1840 patients were randomised (IQCS group: 919, routine group: 921). The full analysis set consisted of 914 in the IQCS group and 915 in the routine group. The early UGI neoplasms detection rate in the IQCS group (6.1%, 56/914) was significantly higher than in the routine group (2.3%, 21/915; <i>P</i> = 0.0001). The IQCS group had fewer blind spots (2.3 vs. 6.2, <i>P</i> < 0.0001). The IQCS group had higher stomach cleanliness on cardia or fundus (99.5% vs. 87.9%, <i>P</i> < 0.0001), body (98.9% vs. 88.0%, <i>P</i> < 0.0001), angulus (99.8% vs. 88.4%, <i>P</i> < 0.0001) and antrum or pylorus (100.0% vs. 87.4%, <i>P</i> < 0.0001). The inspection time (576.2 vs. 574.5s, <i>P</i> = 0.91) and biopsy rate (57.2% vs. 56.6%, <i>P</i> = 0.83) were not different between the groups. The early UGI neoplasms detection rate in the IQCS group increased in both non-academic centres (RR = 3.319, 95% CI 1.277-9.176; <i>P</i> = 0.0094) and academic centres (RR = 2.416, 95% CI 1.301-4.568; <i>P</i> = 0.0034). The same improvements were observed for both less-experienced endoscopists (RR = 2.650, 95% CI 1.330-5.410; <i>P</i> = 0.0034) and experienced endoscopists (RR = 2.710, 95% CI 1.226-6.205; <i>P</i> = 0.010). No adverse events or serious adverse events were reported in the two groups.</p><p><strong>Interpretation: </strong>The IQCS improved the OGD quality and increased early UGI neoplasm detection in different hospital types and endoscopist experiences. IQCS could play an important role in primary basic hospitals and non-expert endoscopists to improve the diagnostic accuracy of early UGI neoplasms. The effectiveness of IQCS in real-world clinical settings needs a larger population validation.</p><p><strong>Funding: </strong>Key R&D Program of Shandong Province, China (Major Scientific and Technological Innovation Project), National Natural Science Foundation of China, the Taishan Scholars Program of Shandong Province, the National Key Research and Development Program of China, and the Shandong Provincial Natural Science Foundation.</p>","PeriodicalId":11393,"journal":{"name":"EClinicalMedicine","volume":"75 ","pages":"102803"},"PeriodicalIF":9.6000,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11402435/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EClinicalMedicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.eclinm.2024.102803","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Oesophagogastroduodenoscopy (OGD) quality and identification of the early upper gastrointestinal (UGI) neoplasm play an important role in detecting the UGI neoplasm. However, the optimal method for quality control in daily OGD procedures is currently lacking. We aimed to evaluate the efficacy of a real-time intelligent quality-control system (IQCS), which combines OGD quality control with lesion detection of early UGI neoplasms.

Methods: We performed a multicentre, single-blinded, randomised controlled trial at 6 hospitals in China. Patients aged 40-80 years old who underwent painless OGD were screened for enrolment in this study. Patients with a history of advanced UGI cancer, stenosis, or obstruction in UGI tract were excluded. Eligible subjects were randomly assigned (1:1) to either the routine or IQCS group to undergo standard OGD examination and OGD examination aided by IQCS, respectively. Patients were masked to the randomisation status. The primary outcome was the detection of early UGI neoplasms. All analyses were done on a per-protocol basis. This trial is registered with ClinicalTrials.gov, NCT04720924.

Findings: Between January 16, 2021 and December 23, 2022, 1840 patients were randomised (IQCS group: 919, routine group: 921). The full analysis set consisted of 914 in the IQCS group and 915 in the routine group. The early UGI neoplasms detection rate in the IQCS group (6.1%, 56/914) was significantly higher than in the routine group (2.3%, 21/915; P = 0.0001). The IQCS group had fewer blind spots (2.3 vs. 6.2, P < 0.0001). The IQCS group had higher stomach cleanliness on cardia or fundus (99.5% vs. 87.9%, P < 0.0001), body (98.9% vs. 88.0%, P < 0.0001), angulus (99.8% vs. 88.4%, P < 0.0001) and antrum or pylorus (100.0% vs. 87.4%, P < 0.0001). The inspection time (576.2 vs. 574.5s, P = 0.91) and biopsy rate (57.2% vs. 56.6%, P = 0.83) were not different between the groups. The early UGI neoplasms detection rate in the IQCS group increased in both non-academic centres (RR = 3.319, 95% CI 1.277-9.176; P = 0.0094) and academic centres (RR = 2.416, 95% CI 1.301-4.568; P = 0.0034). The same improvements were observed for both less-experienced endoscopists (RR = 2.650, 95% CI 1.330-5.410; P = 0.0034) and experienced endoscopists (RR = 2.710, 95% CI 1.226-6.205; P = 0.010). No adverse events or serious adverse events were reported in the two groups.

Interpretation: The IQCS improved the OGD quality and increased early UGI neoplasm detection in different hospital types and endoscopist experiences. IQCS could play an important role in primary basic hospitals and non-expert endoscopists to improve the diagnostic accuracy of early UGI neoplasms. The effectiveness of IQCS in real-world clinical settings needs a larger population validation.

Funding: Key R&D Program of Shandong Province, China (Major Scientific and Technological Innovation Project), National Natural Science Foundation of China, the Taishan Scholars Program of Shandong Province, the National Key Research and Development Program of China, and the Shandong Provincial Natural Science Foundation.

检测早期上消化道肿瘤的实时智能质量控制系统的功效:一项多中心、单盲、随机对照试验。
背景:食管胃十二指肠镜检查(OGD)的质量和早期上消化道(UGI)肿瘤的识别在发现上消化道肿瘤方面发挥着重要作用。然而,目前尚缺乏对日常 OGD 过程进行质量控制的最佳方法。我们旨在评估实时智能质量控制系统(IQCS)的效果,该系统将胃肠造影质量控制与早期 UGI 肿瘤的病变检测相结合:我们在中国的 6 家医院开展了一项多中心、单盲、随机对照试验。我们筛选了年龄在 40-80 岁之间、接受过无痛尿道造影术的患者作为研究对象。排除有晚期胃肠道癌症、胃肠道狭窄或阻塞病史的患者。符合条件的受试者被随机分配(1:1)到常规组或 IQCS 组,分别接受标准 OGD 检查和 IQCS 辅助 OGD 检查。患者的随机分组情况均被掩盖。主要结果是早期胃肠道肿瘤的检出率。所有分析均按方案进行。该试验已在ClinicalTrials.gov注册,编号为NCT04720924:2021年1月16日至2022年12月23日期间,1840名患者接受了随机治疗(IQCS组:919人,常规组:921人)。完整的分析集包括 IQCS 组 914 人和常规组 915 人。IQCS 组的早期 UGI 肿瘤检出率(6.1%,56/914)明显高于常规组(2.3%,21/915;P = 0.0001)。IQCS 组盲点较少(2.3 对 6.2,P = 0.91),活检率(57.2% 对 56.6%,P = 0.83)在组间无差异。在非学术中心(RR = 3.319,95% CI 1.277-9.176;P = 0.0094)和学术中心(RR = 2.416,95% CI 1.301-4.568;P = 0.0034),IQCS 组的早期 UGI 肿瘤检出率均有所提高。经验较少的内镜医师(RR = 2.650,95% CI 1.330-5.410;P = 0.0034)和经验丰富的内镜医师(RR = 2.710,95% CI 1.226-6.205;P = 0.010)也有同样的改善。两组患者均未发生不良事件或严重不良事件:IQCS提高了OGD质量,增加了不同医院类型和内镜医师经验的早期UGI肿瘤检测率。IQCS可在基层医院和非专业内镜医师提高早期消化道肿瘤诊断准确性方面发挥重要作用。IQCS在实际临床环境中的有效性还需要更多人群的验证:山东省重点研发计划(重大科技创新项目)、国家自然科学基金、山东省泰山学者计划、国家重点研发计划、山东省自然科学基金。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
EClinicalMedicine
EClinicalMedicine Medicine-Medicine (all)
CiteScore
18.90
自引率
1.30%
发文量
506
审稿时长
22 days
期刊介绍: eClinicalMedicine is a gold open-access clinical journal designed to support frontline health professionals in addressing the complex and rapid health transitions affecting societies globally. The journal aims to assist practitioners in overcoming healthcare challenges across diverse communities, spanning diagnosis, treatment, prevention, and health promotion. Integrating disciplines from various specialties and life stages, it seeks to enhance health systems as fundamental institutions within societies. With a forward-thinking approach, eClinicalMedicine aims to redefine the future of healthcare.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信